RVMD
Revolution Medicines, Inc.77.56
-1.44-1.82%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Flags PDAC crossover risks, reaffirms plans
Q&A largely reaffirmed Revolution Medicines' pipeline momentum but surfaced potential crossover risks to first-line PDAC trials if daraxonrasib secures second-line approval, with management eyeing timing buffers and ex-US enrollment to mitigate. They recommitted to daraxonrasib in frontline NSCLC while dose-optimizing combos like pembro-chemo and Ivonescimab. Anecdotes of continuing daraxonrasib beyond progression drew encouragement for newer studies. CRC stays prioritized despite combo complexities, pursued standalone. Crossover looms as key risk. Management dodged 302 readout specifics. Investors eye H1 2026 data durability.
Key Stats
Market Cap
14.99BP/E (TTM)
-Basic EPS (TTM)
-5.19Dividend Yield
0%Recent Filings
8-K
Q3 loss widens on trials
Revolution Medicines reported Q3 2025 net loss of $305.2M, up from $156.3M last year, driven by ramped R&D at $262.5M amid daraxonrasib's Phase 3 advances. RASolute 302 enrollment winds down, eyeing 2026 readout; new RASolute 304 and 303 trials target PDAC settings. Cash sits at $1.93B. Leadership bolstered for commercialization.
10-Q
Q3 FY2025 results
Revolution Medicines ramped R&D spend 73% y/y to $262.5M in Q3 ended September 30, 2025, driving operating loss wider to $315.3M from $175.7M y/y (derived) and net loss to $305.2M or $(1.61) diluted EPS on 189.2M shares, up from $(0.94) on 166.8M shares y/y; nine-month net loss hit $766.4M or $(4.06) EPS. Cash burn accelerated with $623.5M nine-month operating outflow, offset by $250M Royalty Pharma royalty-sale proceeds, leaving $1.9B in cash and marketable securities at quarter-end versus $2.3B year-end. No debt drawn; $256.5M royalty-sale liability emerged with $11.4M Q3 non-cash interest. R&D surged on daraxonrasib (Phase 3 RASolute 302 readout eyed 2026), zoldonrasib, elironrasib trials. Clinical delays loom amid fierce RAS inhibitor competition.
8-K
Daraxonrasib PDAC data shines
Revolution Medicines disclosed promising Phase 1 data for daraxonrasib in RAS-mutant PDAC on September 10, 2025. Second-line patients at 300mg daily posted 35% ORR, 8.5-month median PFS; first-line monotherapy hit 47% ORR; combo with GnP reached 55% ORR. Rash and GI issues dominated TRAEs, yet no discontinuations in 2L. Plans advance to Phase 3 RASolute 303 trial.
10-Q
Q2 FY2025 results
Revolution Medicines ramped R&D spend 66% y/y to $224.1M in Q2 FY2025 ended June 30, driving a $113.6M y/y wider operating loss to $264.7M, while net loss widened to $247.8M ($1.31/share) from $133.2M ($0.81/share) on higher expenses and a $6.5M unfavorable warrant fair value swing. R&D jumped on daraxonrasib (RMC-6236) clinical/manufacturing costs up $46.7M y/y, zoldonrasib (RMC-9805) up $8.8M y/y, and headcount. Cash dipped to $2.1B from $2.3B y/y, bolstered by $250M Royalty Pharma royalty sale (liability $245.1M); op cash burn $416.2M YTD (derived). No debt drawn. Clinical trials advance. Competition from KRAS inhibitors looms.
8-K
Q2 loss widens; cash at $2.1B
EDIT
Editas Medicine, Inc.
2.51+0.07
ERAS
Erasca, Inc.
3.52+0.09
IDYA
IDEAYA Biosciences, Inc.
33.81+0.44
IMRX
Immuneering Corporation
5.74-0.04
ONC
BeOne Medicines Ltd.
304.31-6.36
RLAY
Relay Therapeutics, Inc.
8.48+0.00
RNXT
RenovoRx, Inc.
0.84-0.10
RPTX
Repare Therapeutics Inc.
2.23+0.03
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
TNGX
Tango Therapeutics, Inc.
8.96-0.16